Disease dynamics as a biomarker – Model-based analysis allows better prediction of treatment success in CML

Together with clinical partners from the United Kingdom, IMB scientists Andrea Gottschalk, Prof. Ingmar Glauche, and Prof. Ingo Roeder were able to show that there is no benefit from quantifying BCR::ABL1 levels from bone marrow over peripheral blood measurements to predict treatment success for patients with chronic myeloid leukaemia (CML). In particular, blood monitoring after dose reduction combined with a model-based trend analysis enables for better predictions of treatment-free remission. These results were recently published in the renowned journal ‘Leukemia’ (IF: 13.4). 

More Details: https://www.nature.com/articles/s41375-025-02853-7